Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

COCHLEAR LIMITED (COH)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CEST
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
05/17COCHLEAR : Patent Issued for Frequency Based Feedback Control (USPTO 9967680)
AQ
05/17COCHLEAR : Patent Issued for Optical Microphone for Implantable Hearing Instrume..
AQ
05/03COCHLEAR : Patent Issued for Suspended Components in Auditory Prostheses (USPTO ..
AQ
05/03COCHLEAR : Patent Issued for Bone Conduction Device Fitting (USPTO 9955270)
AQ
05/03COCHLEAR : ee Sound Differently,' take the #MillionEar Challenge to protect your..
AQ
04/30COCHLEAR : Launches ‘See Sound Differently’ Video Campaign for Bette..
AQ
04/19COCHLEAR : Patent Issued for Devices for Enhancing Transmissions of Stimuli in A..
AQ
04/13COCHLEAR : Federal Contracts Awarded by Federal Agencies in Texas (April 13)
AQ
04/13COCHLEAR : MILITARY $21,397 Federal Contract Awarded to Cochlear Americas
AQ
03/22COCHLEAR : Patent Issued for Alternate Stimulation Strategies for Perception of ..
AQ
More news
News from SeekingAlpha
01/29Dividend Investing Has Made Me A Better Growth Investor 
2017Apple and Cochlear announce Sound Processor for hearing implant 
2017WEEK IN REVIEW : BGI Genomics Completes $81-Million Chi-Next IPO 
2016How Do I Manage A Favorite Holding That's Now Overvalued? 
2016Smaller Medtechs In Charge Of Their Own Destiny 
Financials ( AUD)
Sales 2018 1 374 M
EBIT 2018 350 M
Net income 2018 247 M
Debt 2018 89,7 M
Yield 2018 1,58%
P/E ratio 2018 45,20
P/E ratio 2019 39,07
EV / Sales 2018 8,20x
EV / Sales 2019 7,40x
Capitalization 11 182 M
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 11
Average target price 164  AUD
Spread / Average Target -16%
EPS Revisions
Managers
NameTitle
Diggory William Howitt President, CEO & Executive Director
Roderick Holliday-Smith Chairman
Brent Cubis Chief Financial Officer
James F. Patrick Chief Scientist & Senior Vice President
Jan Janssen Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED13.47%8 444
SONOVA HOLDING10.48%11 500
STRAUMANN HOLDING-2.76%10 730
INSULET CORPORATION29.22%5 453
DENTIUM CO LTD--.--%900
MODERN DENTAL GROUP LTD4.13%287